242 related articles for article (PubMed ID: 22083217)
1. Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.
Combs CE; Fuller K; Kumar H; Albert AP; Pirianov G; McCormick J; Locke IC; Chambers TJ; Lawrence KM
J Endocrinol; 2012 Feb; 212(2):187-97. PubMed ID: 22083217
[TBL] [Abstract][Full Text] [Related]
2. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
[TBL] [Abstract][Full Text] [Related]
3. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
4. Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors.
Itoh K; Udagawa N; Matsuzaki K; Takami M; Amano H; Shinki T; Ueno Y; Takahashi N; Suda T
J Bone Miner Res; 2000 Sep; 15(9):1766-75. PubMed ID: 10976996
[TBL] [Abstract][Full Text] [Related]
5. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
[TBL] [Abstract][Full Text] [Related]
6. Nitrogen-containing bisphosphonate, YM529/ONO-5920 (a novel minodronic acid), inhibits RANKL expression in a cultured bone marrow stromal cell line ST2.
Nishida S; Tsubaki M; Hoshino M; Namimatsu A; Uji H; Yoshioka S; Tanimori Y; Yanae M; Iwaki M; Irimajiri K
Biochem Biophys Res Commun; 2005 Mar; 328(1):91-7. PubMed ID: 15670755
[TBL] [Abstract][Full Text] [Related]
7. BSP and RANKL induce osteoclastogenesis and bone resorption synergistically.
Valverde P; Tu Q; Chen J
J Bone Miner Res; 2005 Sep; 20(9):1669-79. PubMed ID: 16059638
[TBL] [Abstract][Full Text] [Related]
8. Expression of mouse osteoclast K-Cl Co-transporter-1 and its role during bone resorption.
Kajiya H; Okamoto F; Li JP; Nakao A; Okabe K
J Bone Miner Res; 2006 Jul; 21(7):984-92. PubMed ID: 16813519
[TBL] [Abstract][Full Text] [Related]
9. Regucalcin stimulates osteoclast-like cell formation in mouse marrow cultures.
Yamaguchi M; Uchiyama S
J Cell Biochem; 2005 Mar; 94(4):794-803. PubMed ID: 15578574
[TBL] [Abstract][Full Text] [Related]
10. Chloroform extract of deer antler inhibits osteoclast differentiation and bone resorption.
Li YJ; Kim TH; Kwak HB; Lee ZH; Lee SY; Jhon GJ
J Ethnopharmacol; 2007 Sep; 113(2):191-8. PubMed ID: 17646068
[TBL] [Abstract][Full Text] [Related]
11. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size.
Lees RL; Heersche JN
J Bone Miner Res; 1999 Jun; 14(6):937-45. PubMed ID: 10352102
[TBL] [Abstract][Full Text] [Related]
12. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis.
Merle B; Itzstein C; Delmas PD; Chenu C
J Cell Biochem; 2003 Oct; 90(2):424-36. PubMed ID: 14505357
[TBL] [Abstract][Full Text] [Related]
13. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
14. Possible involvement of corticotropin-releasing factor receptor signaling on vascular inflammation.
Inada Y; Ikeda K; Tojo K; Sakamoto M; Takada Y; Tajima N
Peptides; 2009 Feb; 30(2):365-72. PubMed ID: 19026699
[TBL] [Abstract][Full Text] [Related]
15. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of osteoclast differentiation and bone resorption by tanshinone IIA isolated from Salvia miltiorrhiza Bunge.
Kim HH; Kim JH; Kwak HB; Huang H; Han SH; Ha H; Lee SW; Woo ER; Lee ZH
Biochem Pharmacol; 2004 May; 67(9):1647-56. PubMed ID: 15081864
[TBL] [Abstract][Full Text] [Related]
17. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
[TBL] [Abstract][Full Text] [Related]
18. Nuclear localization of type I parathyroid hormone/parathyroid hormone-related protein receptors in deer antler osteoclasts: evidence for parathyroid hormone-related protein and receptor activator of NF-kappaB-dependent effects on osteoclast formation in regenerating mammalian bone.
Faucheux C; Horton MA; Price JS
J Bone Miner Res; 2002 Mar; 17(3):455-64. PubMed ID: 11874237
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of osteoclast differentiation and bone resorption by a novel lysophosphatidylcholine derivative, SCOH.
Kwak HB; Lee SW; Li YJ; Kim YA; Han SY; Jhon GJ; Kim HH; Lee ZH
Biochem Pharmacol; 2004 Apr; 67(7):1239-48. PubMed ID: 15013839
[TBL] [Abstract][Full Text] [Related]
20. S 12911-2 inhibits osteoclastic bone resorption in vitro.
Takahashi N; Sasaki T; Tsouderos Y; Suda T
J Bone Miner Res; 2003 Jun; 18(6):1082-7. PubMed ID: 12817762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]